Pharming Group N.V. (PHAR) Stock Analysis & Winston Score

Pharming Group N.V. is a Dutch biotechnology company that makes medicines for rare, life-threatening diseases. Its main product is RUCONEST, a protein replacement therapy used to treat hereditary angioedema (HAE), a genetic condition that causes sudden, painful swelling attacks. The company sells primarily to hospitals and specialty pharmacies, serving patients in the United States and Europe. Pharming earns money by selling its approved medicines directly to healthcare providers and through distribution partners. The U.S. market generates the majority of its revenue, and the company has expanded its pipeline by licensing additional rare disease drugs, including leniolisib, approved in 2023 for a rare immune disorder. Its moat comes from orphan drug designations and the complexity of manufacturing protein-based biologics, which creates high barriers for competitors. The key risk is its heavy dependence on a small number of products — any loss of market share or pricing pressure in the HAE market could significantly hurt revenue.